Tryngolza (autoinjector) Patent Expiration

Tryngolza (autoinjector) is a drug owned by Ionis Pharmaceuticals Inc. It is protected by 5 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 01, 2034. Details of Tryngolza (autoinjector)'s patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US9181549 Conjugated antisense compounds and their use
May, 2034

(9 years from now)

Active
US9163239 Compositions and methods for modulating apolipoprotein C-III expression
May, 2034

(9 years from now)

Active
US9127276 Conjugated antisense compounds and their use
May, 2034

(9 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9593333 Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
Feb, 2034

(8 years from now)

Active
US9157082 Modulation of apolipoprotein CIII (ApoCIII) expression
Apr, 2032

(7 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Tryngolza (autoinjector) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tryngolza (autoinjector)'s family patents as well as insights into ongoing legal events on those patents.

Tryngolza (autoinjector)'s Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Tryngolza (autoinjector)'s generic launch date based on the expiry of its last outstanding patent is estimated to be May 01, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Tryngolza (autoinjector) Generics:

There are no approved generic versions for Tryngolza (autoinjector) as of now.





About Tryngolza (autoinjector)

Tryngolza (Autoinjector) is a drug owned by Ionis Pharmaceuticals Inc. Tryngolza (Autoinjector) uses Olezarsen Sodium as an active ingredient. Tryngolza (Autoinjector) was launched by Ionis Pharms Inc in 2024.

Approval Date:

Tryngolza (autoinjector) was approved by FDA for market use on 19 December, 2024.

Active Ingredient:

Tryngolza (autoinjector) uses Olezarsen Sodium as the active ingredient. Check out other Drugs and Companies using Olezarsen Sodium ingredient

Dosage:

Tryngolza (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) SOLUTION Prescription SUBCUTANEOUS